Fig. 6: Schematic of copper chelation therapy.

a Schematic showing copper induced hepatic stem cell depletion. b Schematic showing the first copper chelation therapy experiment. c Hepatic PA signal intensity for mice treated with vehicle in the first copper chelation therapy experiment. Mice are imaged at day 0, 20 40 and 60 with LCP-PA (n = 3 biological replicates). d Hepatic PA signal intensity for mice treated with ATN-224 in the first copper chelation therapy experiment. Mice are imaged at day 0, 20 40 and 60 with LCP-PA (n = 3 biological replicates). e Normalized ALDH1A1 levels from the mass spectrometric analysis for the mice in the first copper chelation therapy study (n = 3 biological replicates). f Schematic showing the second copper chelation therapy experiment. g Normalized ALDH1A1 level from the mass spectrometric analysis for the mice in the second copper chelation study (n = 5 biological replicates for vehicle and n = 4 biological replicates for ATN-224). h Immunohistostaining of ALDH1A1 in mouse liver sample (ALDH1A1 is stained brown). Scale bar = 100 μm. All data is reported as the mean ± standard deviation. Error bars = SD. Statistical analysis was performed using a two-tailed Mann Whitney U test. Source data are provided as a Source Data file.